Name: Name:OSI-027
Brand: AABLOCKS
SKU: AA00GU2E
Rating: 90 (10 reviews)

Catalog No.: AA00GU2E

936890-98-1 | OSI-027

Pack Size： 1mg

Purity： 98%

in stock

$29.00 $20.00

Pack Size： 5mg

Purity： 98%

in stock

$73.00 $51.00

Pack Size： 10mg

Purity： 98%

in stock

$108.00 $76.00

Pack Size： 50mg

Purity： 98%

in stock

$294.00 $206.00

Quantity

- +

Add to Card

Order Now

bulk Quotation Request

Technical Information

Catalog Number: AA00GU2E

Chemical Name: OSI-027

CAS Number: 936890-98-1

Molecular Formula: C21H22N6O3

Molecular Weight: 406.4378

MDL Number: MFCD20275101

SMILES: COc1cccc2=C/C(=c\3/nc(n4c3c(N)nc[nH]4)C3CCC(CC3)C(=O)O)/N=c12

Properties

Complexity: 630

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 0

Defined Bond Stereocenter Count: 0

Formal Charge: 0

Heavy Atom Count: 30

Hydrogen Bond Acceptor Count: 7

Hydrogen Bond Donor Count: 3

Isotope Atom Count: 0

Rotatable Bond Count: 4

Undefined Atom Stereocenter Count: 0

Undefined Bond Stereocenter Count: 0

XLogP3: 2

Downstream Synthesis Route

103-49-1

936890-98-1

[1]CurrentPatentAssignee:ASTELLASPHARMAINC-WO2011/5909,2011,A2

936890-98-1

77-86-1

1187559-63-2

[1]CurrentPatentAssignee:ASTELLASPHARMAINC-WO2011/5909,2011,A2Locationinpatent:Page/Pagecolumn14-15

936902-01-1

936890-98-1

[1]CurrentPatentAssignee:ASTELLASPHARMAINC-WO2011/5909,2011,A2

936902-00-0

936890-98-1

[1]CurrentPatentAssignee:ASTELLASPHARMAINC-WO2011/5909,2011,A2

Literature fold

Title: Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.

Journal: Journal of medicinal chemistry20110310

Title: Falcon BL, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011 Mar 1;71(5):1573-83.

Title: Mateo J, et al. A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. Br J Cancer. 2016;114(8):889-896.

Title: Zhang Y, et al. PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. EBioMedicine. 2015 Nov 19;2(12):1944-56.

Title: Zhi X, et al. OSI-027 modulates acute graft-versus-host disease after liver transplantation in a rat model. Liver Transpl. 2017 Sep;23(9):1186-1198.

Building Blocks More >